Cowen & Co. Reaffirms Their Buy Rating on Alector (ALEC)

By Jason Carr

In a report released yesterday, Yaron Werber from Cowen & Co. maintained a Buy rating on Alector (ALECResearch Report). The company’s shares closed last Monday at $19.76.

According to, Werber is a 5-star analyst with an average return of 19.5% and a 70.8% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Springworks Therapeutics, and Rocket Pharmaceuticals.

Currently, the analyst consensus on Alector is a Moderate Buy with an average price target of $28.00.

See today’s analyst top recommended stocks >>

The company has a one-year high of $27.00 and a one-year low of $13.64. Currently, Alector has an average volume of 402.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Alector, Inc. operates as a clinical-stage biopharmaceutical company. It develops therapeutics for the treatment of neurodegenerative diseases including frontotemporal dementia (FTD), Alzheimer’s disease, and Parkinson’s disease.